NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ARIXTRA (fondaparinux sodium) by Viatris (2) is (atiii)-mediated selective inhibition of factor xa. Approved for venous thromboembolism, pulmonary embolism, thromboembolism. First approved in 2001.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARIXTRA (fondaparinux sodium) is a selective Factor Xa inhibitor that works by potentiating antithrombin III-mediated neutralization of Factor Xa, interrupting the coagulation cascade. It is indicated for prevention and treatment of venous thromboembolism, pulmonary embolism, and thromboembolism in cardiovascular disease. The drug is administered subcutaneously and does not inactivate thrombin or affect platelet function.
$0.219MPart D
LOE ApproachingDeclining
Product is entering late-stage lifecycle with declining Part D claims, signaling reduced team investment and market consolidation.
Mechanism of Action
(ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and…
Indications (3)
Worked on ARIXTRA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.